SMARTSTREAM
15.3.2022 10:02:07 CET | Business Wire | Press release
SmartStream Technologies, the financial Transaction Lifecycle Management (TLM® ) solutions provider, today announces how their AI-enabled technology, combined with specialist reference data in the cloud will help firms meet reporting obligations.
This is the first solution in the industry to combine reference data with reconciliations – with SmartStream RDU (Reference Data Utility) and SmartStream Air (Artificial Intelligence Reconciliations) – the new solution Transaction Reporting Reconciliation and Reporting Decision Control will provide comprehensive disclosure capabilities for MiFID II.
SmartStream has developed this new product to help financial firms demonstrate to the regulators the completeness and accuracy of their transaction reporting process. At the heart of this is SmartStream’s AI-based application, SmartStream Air – which will handle huge complexity and large volumes of data in the cloud. It will reconcile all fields firms may need to enter for MiFID II transaction reporting purposes - offering near real-time matching. SmartStream Air will manage diverse data structures typically found in financial institutions’ source systems – with the new product, firms can now prove the integrity of their data, but without the effort and overheads associated with several reconciliations systems.
SmartStream Air is complemented by SmartStream RDU’s API that will allow firms to validate whether a financial instrument is Traded on a Trading Venue (ToTV), and therefore reportable. SmartStream RDU will offer a wealth of data from regulatory and industry bodies, assisting firms with their trade and transaction reporting, including avoiding either under or over-reporting.
Jethro MacDonald, Product Manager - Innovations Lab, SmartStream, states: “Clearly the FCA is already taking tough measures and has recently imposed large fines on banks where it considers failings have occurred on an extensive, long-term basis. Complying with the demands of MiFID II transaction reporting is complex, also proving data integrity to regulators can place a real strain on firms. This new solution will add an invaluable control for investment firms, allowing them to spot both data, and reporting decision irregularities in one control framework - showcasing to regulators that they've taken all the necessary steps to ensure their transaction reporting is both complete and accurate”.
In addition, the solution will also provide market participants with the necessary data to support their decision to file a report, or not, should that decision be questioned by regulators. In the future, it may even be possible to make anonymised correlations between users, creating a benchmark so that firms can check whether they are reporting in line with their peers.
End
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005224/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Egon Zehnder and IMD Join Forces to Boost Board Performance and Leadership Growth12.3.2026 09:00:00 CET | Press release
Egon Zehnder, the world’s premier leadership advisory and executive search firm, and IMD, the leading business school in global executive education, today announced a strategic partnership to facilitate board directors’ personal growth and elevate board performance. The partnership combines IMD's academic rigor and deep connections to global boards with Egon Zehnder's unparalleled expertise in leadership and board effectiveness. Together, they will co-create tailored development experiences that blend research, real-world diagnostics, and practical guidance to support directors navigating today's complex business environment. IMD’s research clearly shows that good governance is a driver of both corporate success and national competitiveness. Egon Zehnder’s global work in supporting the personal development of board directors and chairs has shown that, in times of accelerating change, this has become a decisive factor for success. “This collaboration comes at a pivotal moment,” said Dav
COOLMAX CloakFX™ Fiber Makes Official Global Debut at Performance Days Munich12.3.2026 09:00:00 CET | Press release
The LYCRA Company’s latest innovation minimizes the visible appearance of sweat while delivering moisture management to activewear, ready-to-wear and workwear The LYCRA Company will officially launch COOLMAX CloakFX™ fiber globally at Performance Days Munich, Europe’s leading functional fabric fair, March 18–19. This innovation is designed to help garments appear drier by minimizing visible sweat marks while delivering moisture management and cooling comfort. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317950119/en/ COOLMAX CloakFX™ fiber, the latest innovation from The LYCRA Company, helps garments appear drier by minimizing visible sweat marks and delivering moisture-wicking, cooling performance. Photo credit: The LYCRA Company COOLMAX CloakFX™ fiber is for brands, mills, and garment makers creating performance-driven activewear, workwear, and everyday apparel. The technology diffuses light at the fiber level using o
EcoOnline Launches Mega Trends Report as 2025 Momentum Reflects the Shift from Compliance to Connected Risk12.3.2026 09:00:00 CET | Press release
Eighteen months of EcoOnline primary research highlights seven shifts reshaping safety and sustainability, mirrored in the company’s 2025 customer adoption, product innovation, and growth. EcoOnline, a leading global provider of safety and sustainability software, today announced its inaugural EcoOnline Mega Trends Report, based on 18 months of primary research with business leaders and frontline workers. Seven mega trends reshaping the risk landscape The findings show a market-wide sense of urgency and shift towards connected risk data and vendor consolidation, with organisations increasingly treating compliance as the baseline while prioritising improved operations visibility, faster decision-making, and a need to future-proof their businesses with real-time insights and operational readiness. The report outlines seven macro trends, from the chemical safety maturity gap and the rise of lone work and contractor reliance to the central role of training and frontline engagement, and the
Redslim expands into Asia-Pacific to support global brands with data and AI infrastructure12.3.2026 07:00:00 CET | Press release
Redslim, a specialist in end-to-end data management solutions and an Astorg portfolio company, today announced its expansion into the Asia-Pacific region and the appointment of Kyriakos Zannikos as Regional Director, APAC. The move marks an important milestone in Redslim’s global growth strategy and brings the company closer to clients operating in one of the world’s fastest-growing and most data-driven consumer markets. As global consumer brands accelerate digital transformation and AI adoption, many organizations still struggle with fragmented data ecosystems spanning multiple agencies, markets and datasets. These challenges are particularly pronounced in Asia-Pacific, where diverse market structures and rapid growth create complex data environments. Redslim helps organizations transform fragmented market information into valuable data assets, empowering clients to make confident decisions and unlock the full value of their data. By building strong data foundations, Redslim supports
Meiji Seika Pharma Initiates Phase I Clinical Trial in Australia Evaluating ME3241, an Anti-PD-1 Agonist Antibody Discovered Through Collaborative Research With FBRI12.3.2026 07:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) announced today that it has initiated a Phase I clinical trial of ME3241 (development code), an anti-PD-1 agonist monoclonal antibody discovered through collaborative research with the Foundation for Biomedical Research and Innovation at Kobe (Headquarters: Kobe, Japan; President: Shuh Narumiya; hereinafter “FBRI”). The Phase I clinical trial is designed as a randomized, placebo-controlled, double-blind study, with the objective of evaluating the safety and tolerability of ME3241 following single and multiple dosing, as well as its pharmacokinetics and pharmacodynamics (ClinicalTrials.gov: NCT07422207). ME3241 was discovered through a collaborative research program led by Program Director Tasuku Honjo, a professor emeritus at Kyoto University. PD-1 is a molecule expressed on activated T cells and other lymphocytes that suppresses immune responses. Through this re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom